Search Results

Vitrolife AB has completed the acquisition of eFertility as previously communicated in the press release on 2 May 2024.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

Medivir AB announces that the number of shares and votes in Medivir has changed during June 2024 as a result of the issue of 1,700,000 shares of series C and the reclassification of 114 587 shares of series C to ordinary shares which was carried out as a part of the implementation of the incentive program resolved by the general meeting on 7 May 2024.

Q4 2022 marked the conclusion of a transformational year for IRRAS, and, as we begin the new year, we have created new opportunities that will accelerate our growth toward achieving leadership in the world of neurocritical care.

Vitrolife AB signed an agreement to acquire 100% of the shares in eFertility. This acquisition is a key element of the Vitrolife Group’s strategy to bring increased standardisation and digitalisation to IVF clinics around the world.

AB Science SA (Euronext - FR0010557264 - AB) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in the treatment of amyotrophic lateral sclerosis (ALS), following an oral explanation held at the 28 May meeting of the CHMP.

The Board of Directors of Calliditas Therapeutics AB unanimously recommends that the shareholders and holders of American Depositary Shares of Calliditas Therapeutics AB accept the public tender offer by Asahi Kasei Corporation.

IRRAS announced and completed a fully subscribed rights issue that raised MSEK 215 before deduction of costs related to the transaction.

AB Science SA reports its revenues for the year 2023 and provides an update on its activities.